159 related articles for article (PubMed ID: 21204727)
1. Non-histone nuclear factor HMGB1 as a therapeutic target in colorectal cancer.
Ohmori H; Luo Y; Kuniyasu H
Expert Opin Ther Targets; 2011 Feb; 15(2):183-93. PubMed ID: 21204727
[TBL] [Abstract][Full Text] [Related]
2. Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1.
van Beijnum JR; Nowak-Sliwinska P; van den Boezem E; Hautvast P; Buurman WA; Griffioen AW
Oncogene; 2013 Jan; 32(3):363-74. PubMed ID: 22391561
[TBL] [Abstract][Full Text] [Related]
3. An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies.
Musumeci D; Roviello GN; Montesarchio D
Pharmacol Ther; 2014 Mar; 141(3):347-57. PubMed ID: 24220159
[TBL] [Abstract][Full Text] [Related]
4. Role of high mobility group box 1 in inflammatory disease: focus on sepsis.
Bae JS
Arch Pharm Res; 2012 Sep; 35(9):1511-23. PubMed ID: 23054707
[TBL] [Abstract][Full Text] [Related]
5. High-mobility group box 1 represents a potential marker of disease activity and novel therapeutic target in systemic lupus erythematosus.
Urbonaviciute V; Voll RE
J Intern Med; 2011 Oct; 270(4):309-18. PubMed ID: 21793951
[TBL] [Abstract][Full Text] [Related]
6. High-mobility group box-1 in ischemia-reperfusion injury of the heart.
Andrassy M; Volz HC; Igwe JC; Funke B; Eichberger SN; Kaya Z; Buss S; Autschbach F; Pleger ST; Lukic IK; Bea F; Hardt SE; Humpert PM; Bianchi ME; Mairbäurl H; Nawroth PP; Remppis A; Katus HA; Bierhaus A
Circulation; 2008 Jun; 117(25):3216-26. PubMed ID: 18574060
[TBL] [Abstract][Full Text] [Related]
7. Dealing with death: HMGB1 as a novel target for cancer therapy.
Lotze MT; DeMarco RA
Curr Opin Investig Drugs; 2003 Dec; 4(12):1405-9. PubMed ID: 14763124
[TBL] [Abstract][Full Text] [Related]
8. Colon cancer cell-derived high mobility group 1/amphoterin induces growth inhibition and apoptosis in macrophages.
Kuniyasu H; Yano S; Sasaki T; Sasahira T; Sone S; Ohmori H
Am J Pathol; 2005 Mar; 166(3):751-60. PubMed ID: 15743787
[TBL] [Abstract][Full Text] [Related]
9. HMGB1 attenuates anti-metastatic defence of the liver in colorectal cancer.
Luo Y; Ohmori H; Fujii K; Moriwaka Y; Sasahira T; Kurihara M; Tatsumoto N; Sasaki T; Yamashita Y; Kuniyasu H
Eur J Cancer; 2010 Mar; 46(4):791-9. PubMed ID: 20018503
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effects of lycopene on HMGB1-mediated pro-inflammatory responses in both cellular and animal models.
Lee W; Ku SK; Bae JW; Bae JS
Food Chem Toxicol; 2012 Jun; 50(6):1826-33. PubMed ID: 22429818
[TBL] [Abstract][Full Text] [Related]
11. Suppression of dendritic cells by HMGB1 is associated with lymph node metastasis of human colon cancer.
Kusume A; Sasahira T; Luo Y; Isobe M; Nakagawa N; Tatsumoto N; Fujii K; Ohmori H; Kuniyasu H
Pathobiology; 2009; 76(4):155-62. PubMed ID: 19571604
[TBL] [Abstract][Full Text] [Related]
12. HMGB1: a two-headed signal regulating tumor progression and immunity.
Campana L; Bosurgi L; Rovere-Querini P
Curr Opin Immunol; 2008 Oct; 20(5):518-23. PubMed ID: 18599281
[TBL] [Abstract][Full Text] [Related]
13. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1).
van Beijnum JR; Buurman WA; Griffioen AW
Angiogenesis; 2008; 11(1):91-9. PubMed ID: 18264787
[TBL] [Abstract][Full Text] [Related]
14. Activation of Toll-like receptor, RAGE and HMGB1 signalling in malformations of cortical development.
Zurolo E; Iyer A; Maroso M; Carbonell C; Anink JJ; Ravizza T; Fluiter K; Spliet WG; van Rijen PC; Vezzani A; Aronica E
Brain; 2011 Apr; 134(Pt 4):1015-32. PubMed ID: 21414994
[TBL] [Abstract][Full Text] [Related]
15. HMGB1 attenuates anti-metastatic defense of the lymph nodes in colorectal cancer.
Moriwaka Y; Luo Y; Ohmori H; Fujii K; Tatsumoto N; Sasahira T; Kuniyasu H
Pathobiology; 2010; 77(1):17-23. PubMed ID: 20185963
[TBL] [Abstract][Full Text] [Related]
16. Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer.
Kuniyasu H; Chihara Y; Takahashi T
Oncol Rep; 2003; 10(2):445-8. PubMed ID: 12579287
[TBL] [Abstract][Full Text] [Related]
17. Extracellular high mobility group box-1 inhibits R5 and X4 HIV-1 strains replication in mononuclear phagocytes without induction of chemokines and cytokines.
Cassetta L; Fortunato O; Adduce L; Rizzi C; Hering J; Rovere-Querini P; Bianchi ME; Alfano M; Poli G
AIDS; 2009 Mar; 23(5):567-77. PubMed ID: 19194273
[TBL] [Abstract][Full Text] [Related]
18. High mobility group box 1 released from necrotic cells enhances regrowth and metastasis of cancer cells that have survived chemotherapy.
Luo Y; Chihara Y; Fujimoto K; Sasahira T; Kuwada M; Fujiwara R; Fujii K; Ohmori H; Kuniyasu H
Eur J Cancer; 2013 Feb; 49(3):741-51. PubMed ID: 23040637
[TBL] [Abstract][Full Text] [Related]
19. Systemic involvement of high-mobility group box 1 protein and therapeutic effect of anti-high-mobility group box 1 protein antibody in a rat model of crush injury.
Shimazaki J; Matsumoto N; Ogura H; Muroya T; Kuwagata Y; Nakagawa J; Yamakawa K; Hosotsubo H; Imamura Y; Shimazu T
Shock; 2012 Jun; 37(6):634-8. PubMed ID: 22392147
[TBL] [Abstract][Full Text] [Related]
20. High-mobility group box-1 in sterile inflammation.
Tsung A; Tohme S; Billiar TR
J Intern Med; 2014 Nov; 276(5):425-43. PubMed ID: 24935761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
